Mira Jung resumes & CV records
Resumes
Mira Jung
Mira E Jung, 51507 Giada Dr, Wilmington, DE 19808
Mira Jung Phones & Addresses
Wilmington, DE
Haymarket, VA
7215 Beverly Park Dr, Springfield, VA 22150 703-9130765
Gainesville, VA
Fairfax, VA
Durham, NC
Prince William, VA
507 Giada Dr, Wilmington, DE 19808
Work
Position:
Professional/Technical
Education
Degree:
High school graduate or higher
Mentions for Mira E Jung
Publications & IP owners
Us Patents
Histone Deacetylase Inhibitors
US Patent:
8293513, Oct 23, 2012
Filed:
Dec 12, 2008
Appl. No.:
12/747365
Inventors:
Milton L. Brown - Brookeville MD, US
Mira O. Jung - Rockville MD, US
Anatoly Dritschilo - Bethesda MD, US
Yali Kong - Centreville VA, US
Mira O. Jung - Rockville MD, US
Anatoly Dritschilo - Bethesda MD, US
Yali Kong - Centreville VA, US
Assignee:
Georgetown University - Washington DC
International Classification:
A61K 31/18
C12N 9/99
C12N 5/09
A61P 35/00
C07C 303/00
C07C 307/00
C07C 309/00
C07C 311/00
C12N 9/99
C12N 5/09
A61P 35/00
C07C 303/00
C07C 307/00
C07C 309/00
C07C 311/00
US Classification:
435184, 435375, 514603, 564 86
Abstract:
Novel histone deacetylase inhibitors, including novel fluorescent histone deacetylase inhibitors, are described. Methods for making and using the same, e. g. , to treat cancer, are provided.
Gene Therapy For Prostate Cancer: Sensibilization Of Cells To Dna Damaging Drugs And Radiation
US Patent:
2004006, Apr 8, 2004
Filed:
Nov 20, 2003
Appl. No.:
10/450411
Inventors:
Viatcheslav Soldatenkov - Washington DC, US
Mira Jung - Washington DC, US
Anatoly Dritschilo - Washington DC, US
Mira Jung - Washington DC, US
Anatoly Dritschilo - Washington DC, US
International Classification:
A61K048/00
C07H021/04
C07H021/04
US Classification:
514/044000, 536/023500, 435/320100
Abstract:
The present invention is directed to a novel therapeutic method for treating prostate cancer. The method employs the tissue-specific PSA promoter/enhancer as well as the unique properties of the DNA binding domain (dbd) of poly (ADP-ribose) polymerase (PARP) as a potent inhibitor of DNA damage repair and as a molecular sensitizer to genotoxic stresses. The sustained presence of the PARP-DBD in prostate tumor tissue induces enhanced tumor cell killing in response to DNA damaging treatments. The invention may be used as a biotherapeutic approach in the treatment of prostate cancers, which fail local-regional therapy, without significant risk of normal tissue damage.
Histone Deacetylase Inhibitors And Methods Of Use Thereof
US Patent:
2005001, Jan 20, 2005
Filed:
Jul 7, 2003
Appl. No.:
10/614498
Inventors:
Alan Kozikowski - Arlington VA, US
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Rockville MD, US
Pavel Petukhov - Rockville MD, US
Bin Chen - Arlington VA, US
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Rockville MD, US
Pavel Petukhov - Rockville MD, US
Bin Chen - Arlington VA, US
International Classification:
A61K031/19
C07C259/04
C07C259/04
US Classification:
514575000, 514357000, 514408000, 562621000
Abstract:
The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
Methods For The Use Of Inhibitors Of Histone Deacetylase As Synergistic Agents In Cancer Therapy
US Patent:
2005022, Oct 6, 2005
Filed:
Jan 16, 2004
Appl. No.:
10/512980
Inventors:
Mira Jung - Rockville MD, US
Manfred Jung - Gundelfingen, DE
Anatoly Dritschilo - Bethesda MD, US
Manfred Jung - Gundelfingen, DE
Anatoly Dritschilo - Bethesda MD, US
Assignee:
Georgetown University - Washington DC
International Classification:
A61K038/12
A61K031/19
A61N005/00
A61K031/19
A61N005/00
US Classification:
514009000, 514575000, 600001000
Abstract:
Improved methods for treatment of cancer are provided. The improvements include the administration of one or more synergistic agents, specifically inhibitors of histone deacetylase proteins and complexes. These synergistic agnets increase the effectiveness of radiation therapy and/or chemotherapies by increasing the sensitivity of tumor cells to treatment.
The P65 Subunit Of Nf-Kb For The Radiosensitization Of Cells
US Patent:
2005028, Dec 29, 2005
Filed:
Feb 19, 2003
Appl. No.:
10/504364
Inventors:
Mira Jung - Washington DC, US
Anatoly Dritschilo - Washington DC, US
Anatoly Dritschilo - Washington DC, US
Assignee:
Georgetown University - Washington DC
International Classification:
A61K039/00
A61K038/18
A61K038/18
US Classification:
424185100, 514012000
Abstract:
The transcription factor NF-κB is activated in response to various stimuli including ionizing radiation. Disruption of NFκB activation by mutant forms of the NF-κB inhibitor IκB-α or by proteasome inhibitors enhances both sensitivity to radiation and radiation-induced apoptasis. The present invention shows that expression of a dominant negative fragment of human p65 (p65DN) leads to down-regulation of both endogenous p65 protein and its mRNA. The dominant negative protein also inhibits radiation-induced NF-κB activation by preventing the proteolysis of IκB-α, resulting in enhancement of cellular radiosensitivity and radiation-induced apoptosis. The region of p65 in the dominant negative fragment is thus a molecular target for disruption of NF-κB activation and sensitization of tumors to radiotherapy.
Delivery System For Therapy Comprising Hollow Seed, The Method Of Use Thereof
US Patent:
2006017, Aug 3, 2006
Filed:
Mar 7, 2006
Appl. No.:
11/368442
Inventors:
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Gaithersburg MD, US
Manny Subramanian - Frederick MD, US
Mira Jung - Gaithersburg MD, US
Manny Subramanian - Frederick MD, US
International Classification:
A61K 9/22
US Classification:
604890100
Abstract:
Hollow metal and polymeric containers (or seeds) are provided having a therapeutic agent encapsulated therein, e.g., a nucleic acid or cytokine, that diffuses out of the seeds via one or more holes disposed therein and is thereby delivered to target sites, e.g., tumor cells. These hollow seeds can be precisely delivered to garget cites, e.g., within a tumor, preferably by use of stereotactic guidance, ultrasound, CT or MRI.
Delivery System For Therapy Comprising Hollow Seed, Preferably Polymeric
US Patent:
2006017, Aug 3, 2006
Filed:
Mar 7, 2006
Appl. No.:
11/368443
Inventors:
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Gaithersburg MD, US
Manny Subramanian - Frederick MD, US
Mira Jung - Gaithersburg MD, US
Manny Subramanian - Frederick MD, US
International Classification:
A61K 9/22
US Classification:
604890100
Abstract:
Hollow metal and polymeric containers (or seeds) are provided having a therapeutic agent encapsulated therein, e.g., a nucleic acid or cytokine, that diffuses out of the seeds via one or more holes disposed therein and is thereby delivered to target sites, e.g., tumor cells. These hollow seeds can be precisely delivered to garget cites, e.g., within a tumor, preferably by use of stereotactic guidance, ultrasound, CT or MRI.
Delivery System For Therapy Comprising Hollow Seeds, And The Method Of Use Thereof
US Patent:
2010014, Jun 10, 2010
Filed:
Dec 23, 2009
Appl. No.:
12/654556
Inventors:
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Gaithersburg MD, US
Manny R. Subramanian - Frederick MD, US
Mira Jung - Gaithersburg MD, US
Manny R. Subramanian - Frederick MD, US
International Classification:
A61K 51/02
A61K 31/7088
A61K 38/19
A61M 36/12
A61K 31/7088
A61K 38/19
A61M 36/12
US Classification:
424 125, 514 44 R, 514 44 A, 514 12, 600 8
Abstract:
Hollow metal and polymeric containers (or seeds) are provided having a therapeutic agent encapsulated therein, e.g., a nucleic acid or cytokine, that diffuses out of the seeds via one or more holes disposed therein and is thereby delivered to target sites, e.g., tumor cells. These hollow seeds can be precisely delivered to garget cites, e.g., within a tumor, preferably by use of stereotactic guidance, ultrasound, CT or MRI.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.